The ATR inhibitor elimusertib exhibits anti-lymphoma activity and synergizes with the PI3K inhibitor copanlisib.
Saved in:
| Title: | The ATR inhibitor elimusertib exhibits anti-lymphoma activity and synergizes with the PI3K inhibitor copanlisib. |
|---|---|
| Authors: | Sartori G; Institute of Oncology Research, Faculty of Biomedical Sciences, USI, Bellinzona, Switzerland., Tarantelli C; Institute of Oncology Research, Faculty of Biomedical Sciences, USI, Bellinzona, Switzerland., Spriano F; Institute of Oncology Research, Faculty of Biomedical Sciences, USI, Bellinzona, Switzerland., Gaudio E; Institute of Oncology Research, Faculty of Biomedical Sciences, USI, Bellinzona, Switzerland., Cascione L; Institute of Oncology Research, Faculty of Biomedical Sciences, USI, Bellinzona, Switzerland.; SIB Swiss Institute of Bioinformatics, Lausanne, Switzerland., Mascia M; Institute of Oncology Research, Faculty of Biomedical Sciences, USI, Bellinzona, Switzerland., Barreca M; Institute of Oncology Research, Faculty of Biomedical Sciences, USI, Bellinzona, Switzerland.; Department of Biological, Chemical and Pharmaceutical Sciences and Technologies (STEBICEF), University of Palermo, Palermo, Italy., Arribas AJ; Institute of Oncology Research, Faculty of Biomedical Sciences, USI, Bellinzona, Switzerland.; SIB Swiss Institute of Bioinformatics, Lausanne, Switzerland., Licenziato L; Institute of Oncology Research, Faculty of Biomedical Sciences, USI, Bellinzona, Switzerland.; Department of Veterinary Sciences, University of Turin, Turin, Italy., Golino G; Institute of Oncology Research, Faculty of Biomedical Sciences, USI, Bellinzona, Switzerland., Ferragamo A; Institute of Oncology Research, Faculty of Biomedical Sciences, USI, Bellinzona, Switzerland., Pileri S; Division of Diagnostic Haematopathology, European Institute of Oncology, Milan, Italy., Damia G; Laboratory of Molecular Pharmacology, Department of Oncology, IRCCS-Istituto di Ricerche Farmacologiche 'Mario Negri', Milan, Italy., Zucca E; Institute of Oncology Research, Faculty of Biomedical Sciences, USI, Bellinzona, Switzerland.; Oncology Institute of Southern Switzerland, EOC, Bellinzona, Switzerland., Stathis A; Oncology Institute of Southern Switzerland, EOC, Bellinzona, Switzerland.; Faculty of Biomedical Sciences, USI, Lugano, Switzerland., Politz O; Bayer AG, Pharmaceuticals, Research & Development, Berlin, Germany., Wengner AM; Bayer AG, Pharmaceuticals, Research & Development, Berlin, Germany., Bertoni F; Institute of Oncology Research, Faculty of Biomedical Sciences, USI, Bellinzona, Switzerland.; Oncology Institute of Southern Switzerland, EOC, Bellinzona, Switzerland. |
| Source: | British journal of haematology [Br J Haematol] 2024 Jan; Vol. 204 (1), pp. 191-205. Date of Electronic Publication: 2023 Nov 27. |
| Publication Type: | Journal Article; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 0372544 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1365-2141 (Electronic) Linking ISSN: 00071048 NLM ISO Abbreviation: Br J Haematol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
